A personalized mRNA cancer vaccine sponsored by Moderna and Merck has the potential to change the standard of care for melanoma patients—and reshape the landscape of cancer vaccines—if the company’s latest data on the vaccine are validated in a phase III clinical trial.
In two raucous back-to-back hearings on Jan. 29 and Jan. 30, anti-vaccine crusader Robert F. Kennedy Jr. was grilled by members of the United States Senate Finance Committee and the Health, Education, Labor, and Pensions Committee as the Trump administration seeks his confirmation as secretary of the Department of Health and Human Services.
